Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Quantitative POC Test Diagnoses and Monitors Microalbuminuria

By Labmedica staff writers
Posted on 24 Jun 2008
A quantitative point-of-care (POC) test screens for, diagnoses, and monitors microalbuminuria, a kidney and cardiovascular disease risk marker.

Microalbuminuria can indicate the presence of chronic kidney disease (CKD), a life-threatening condition that affects approximately 26 million individuals in the United States alone. More...
Diabetes and hypertension are the two leading risk factors for developing CKD. Microalbuminuria also is an independent risk factor for developing cardiovascular disease in patients with or without diabetes or hypertension.

A condition characterized by the presence of albumin, a protein, excreted in urine, microalbuminuria identification and quantitation supplements clinical evidence in the treatment of the medical condition. The HemoCue (Angelholm, Sweden) Albumin 201 system enables physicians to identify and quantify low levels of albumin at POC within 90 seconds.

A study published in the February 2008 American Journal of Nephrology concluded that the "HemoCue Albumin 201 system is a valid and precise method for urinary albumin excretion (UAE) determination, exhibiting a performance similar to laboratory albumin-to-creatinine (ACR) estimations and far better than the widely used dipsticks... the HemoCue Albumin 201 system appears to be a convenient solution for detection of abnormal UAE levels.” The study involved 165 adult subjects under treatment for hypertension at the Rush University Medical Center (Chicago, IL, USA). Professor George L. Bakris, M.D., director of the hypertensive diseases unit at the University of Chicago-Pritzker School of Medicine (Chicago, IL, USA) was the study's lead investigator.

HemoCue, a diagnostic test manufacturer and wholly owned subsidiary of Quest Diagnostics, Inc. (Madison, NJ, USA) announced that its HemoCue Albumin 201 system has been granted a Clinical Laboratory Improvement Amendments (CLIA) waiver by the U.S. Food and Drug Administration (FDA; Rockville, MD, USA). This will enable non-laboratory trained physicians and other healthcare professionals in U.S. health care facilities with CLIA Waivers to use the HemoCue Albumin 201 system to screen patients for microalbuminuria and begin treatment based on the test's results during a single office visit.


Related Links:
HemoCue
Rush University Medical Center
Quest Diagnostics

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Nucleic Acid Purification Instrument
QIAsymphony Connect
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.